Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more
recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in …

Cell culturing is a cornerstone of tissue engineering, playing a crucial role in tissue
regeneration, drug screening, and the study of disease mechanisms. Among various …

Aim To assess cause‐specific death in patients with heart failure with preserved, mildly
reduced, and reduced ejection fraction (HFpEF, HFmrEF, and HFrEF). Methods and results …

Background The triglyceride glucose-body mass (TyG-BMI) index is acknowledged as both
a reliable indicator of the risk of cardiovascular disease and an accurate surrogate …

Heart failure with preserved ejection fraction (HFpEF) is a multi-organ systemic syndrome
that involves cardiac and extra-cardiac pathophysiological abnormalities. Its growing …

Background: Current risk stratification strategies for heart failure (HF) risk require either
specific blood-based biomarkers or comprehensive clinical evaluation. In this study, we …

Background Current heart failure (HF) guidelines recommend a multidisciplinary approach,
discharge education, and self-management for HF. However, the recommendations are …

BACKGROUND: The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for
Management of Heart Failure) found no significant difference in all-cause mortality or …

Doxorubicin is an effective drug for cancer treatment; however, cardiotoxicity limits its use.
Cardiotoxicity pathophysiology is multifactorial. GLP-1 analogues have been shown to …

Guideline‐directed medical therapy (GDMT) in patients with heart failure and reduced
ejection fraction (HFrEF) reduces morbidity and mortality, but its implementation is often poor …